Medlab expands into Europe

The company said meetings have been held with the European regulator on the pathway for registration of NanaBis. Registration with a significant fee reduction requires the company to be domiciled in Europe, it said in a statement.

“MDC as a Group is strategically placed to progress commerce in Europe through potential trade deals, especially in conjunction with the recently announced granting of an export licence for NanaBis. This move is also very exciting as it provides NanaBis an introduction into Europe as a potentially future compliant drug," said Medlab CEO Dr Sean Hall.